Study Evaluating Serum Collected From Healthy Adults For Development of Pneumococcal Opsonophagocytic Assay

Pfizer152 enrolled

Overview

The study will identify healthy adults who have been vaccinated against pneumococcus, and collect blood for the purpose of developing laboratory assays.

Collect serum with antibody levels capable of killing pneumococcal bacteria from healthy prevaccinated adults to develop OPA assays for the 13 serotypes in 13-valent pneumococcal conjugate vaccine.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Enrollment

152

Conditions

Healthy

Interventions

Large volume blood drawPROCEDURE

Large volume blood draw

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy adults 18-70 years of age * Must have received 23vPS pneumococcal vaccine Exclusion Criteria: * Bleeding diathesis * Pregnancy * Chronic disease which could be worsened by donating blood * Receipt of blood, blood products or immune globulin within six months

Locations (1)

Frontage Clinical Services Inc.

Secaucus, New Jersey, United States

Outcomes

Primary Outcomes

To identify potential serum donors and obtain unit volumes of blood from these donors for use in pneumococcal opsonophagocytic assay development.

Time frame: 8 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.